000
| 02042nam 2200301za 4500 |
---|
001 | 9.847765 |
---|
003 | CaOODSP |
---|
005 | 20221107153520 |
---|
007 | cr ||||||||||| |
---|
008 | 171124s2018 onc o f000 0 eng d |
---|
020 | |a9780660240114|z9780660240121 |
---|
040 | |aCaOODSP|beng |
---|
043 | |an-cn--- |
---|
086 | 1 |aNR16-182/2017E-PDF |
---|
110 | 2 |aNational Research Council Canada. |
---|
245 | 10|aExtending in vivo half-life of therapeutic proteins (L-11944) |h[electronic resource]. |
---|
260 | |a[Ottawa] : |bNational Research Council Canada, |c[2018] |
---|
300 | |a[1] p. |
---|
500 | |aIssued also in French under title: Accroître la demi-vie in vivo des protéines thérapeutiques (L-11944). |
---|
500 | |aCaption title. |
---|
500 | |a"December 2017." |
---|
520 | |a“Post-translational modifications of therapeutic proteins are commonly made to improve their circulating half-life, thereby enhancing their efficiency. Numerous strategies have been employed towards this end, including covalent modification, such as through PEGylation, the chemical addition of chains of polyethylene glycol (PEG) to therapeutic proteins. However, PEGylation relies on chemical conjugation of PEG chains to free amino groups or engineered cysteine residues on the protein, which can lead to heterogeneously-modified proteins whose activity can be adversely affected. To address this, the NRC has developed a site-specific, two-step in vitro modification process whereby polysialic acid (PSA) is enzymatically added to existing glycans, resulting in proteins with greater stability, solubility and circulating half-life”--Highlights. |
---|
530 | |aIssued also in print format. |
---|
693 | 4|aRecombinant proteins |
---|
693 | 4|aProtein engineering |
---|
775 | 08|tAccroître la demi-vie in vivo des protéines thérapeutiques (L-11944) |w(CaOODSP)9.847777 |
---|
776 | 0#|tExtending in vivo half-life of therapeutic proteins |w(CaOODSP)9.847766 |
---|
856 | 40|qPDF|s122 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-182-2017-eng.pdf |
---|